holmium has been researched along with lutetium lu 177 dotatate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braat, AJAT; de Herder, WW; de Jong, HWAM; Dreijerink, KMA; Kam, BLR; Krijger, GC; Kwekkeboom, DJ; Lam, MGEH; Teunissen, JJM; van den Bosch, MAAJ; van Rooij, R | 1 |
| Braat, AJAT; Braat, MNGJA; Bruijnen, RCG; de Herder, WW; de Jong, HWAM; Hofland, J; Lam, MGEH; Tesselaar, MET; van Leeuwaarde, RS; van Rooij, R; van Treijen, MJC; Wessels, FJ | 1 |
2 trial(s) available for holmium and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Additional hepatic
Topics: Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Embolization, Therapeutic; Holmium; Humans; Liver Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Quality of Life; Radioisotopes; Radiopharmaceuticals; Remission Induction; Survival Analysis | 2018 |
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Topics: Aged; Embolization, Therapeutic; Female; Holmium; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Prospective Studies; Radioisotopes; Treatment Outcome | 2020 |